Title:
クプリアウィドゥス属細菌由来のナノ小胞及びその使用
Document Type and Number:
Japanese Patent JP6959664
Kind Code:
B2
Abstract:
The present invention relates to vesicles derived from bacteria belonging to the genusCupriavidusand a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangio carcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, and depression, and the like as compared to normal individuals, and the vesicles significantly suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from bacteria belonging to the genusCupriavidusmay be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression, and a composition for preventing or treating the diseases.
More Like This:
Inventors:
Kim, Yun-Kun
Application Number:
JP2019548319A
Publication Date:
November 02, 2021
Filing Date:
February 20, 2019
Export Citation:
Assignee:
MD HEALTHCARE INC.
International Classes:
C12Q1/06; A23L33/135; A61K35/74; A61P3/10; A61P9/00; A61P9/06; A61P11/00; A61P13/12; A61P25/16; A61P25/24; A61P25/28; A61P35/00; C12N1/20; C12N15/11; C12Q1/689; G01N33/50; G01N33/53
Domestic Patent References:
| JP2017517569A | ||||
| JP2020503032A | ||||
| JP2020501562A | ||||
| JP2020501563A | ||||
| JP2020503028A | ||||
| JP2020508067A |
Foreign References:
| WO2018008895A1 | ||||
| WO2018030732A1 | ||||
| WO2017009693A1 |
Other References:
Tumor Biology,2016年,Vol.37,p.15835-15845
Journal of Microbiology and Biotechnology,2017年,Vol.27, No.4,p.791-807
Journal of Microbiology and Biotechnology,2017年,Vol.27, No.4,p.791-807
Attorney, Agent or Firm:
Patent Business Corporation Unias International Patent Office
Previous Patent: Heterocyclic compounds as FGFR inhibitors
Next Patent: Nanovesicles derived from Proteus bacteria and their uses
Next Patent: Nanovesicles derived from Proteus bacteria and their uses